Scarica l'app Stockscreener
68.95
3.75%
2.49
Pre-mercato:
69.50
0.55
+0.80%
Oruka Therapeutics Inc Borsa (ORKA) Ultime notizie
Oruka Therapeutics shares jump on strong psoriasis trial results - MSN
Fairmount funds keep 19.99% Oruka (ORKA) stake under 45-day lock-up - Stock Titan
Assessing Oruka Therapeutics (ORKA) Valuation After Phase 2a Psoriasis Success And Once‑Yearly Dosing Potential - Sahm
Oruka Therapeutics Insider Sold Shares Worth $319,384, According to a Recent SEC Filing - marketscreener.com
ORKA SEC FilingsOruka Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Oruka Therapeutics COO Laura Sandler sells $319,384 in Orka shares By Investing.com - Investing.com Canada
Oruka Therapeutics COO Laura Sandler sells $319,384 in Orka shares - Investing.com
Oruka Therapeutics (ORKA) COO sells 5,000 shares and exercises 5,000-share warrant - Stock Titan
Oruka Therapeutics Completes Public Equity Offering Under Shelf - The Globe and Mail
Three biotechs raise $850M+ in upsized IPOs, gain in aftermarket: Public Equity Report - biocentury.com
Finance Watch: Avalyn, Hemab And Seaport Launch $856m Worth Of IPOs - Citeline News & Insights
Laura Sandler to sell 10,000 ORKA shares (ORKA) via option exercise - Stock Titan
Oruka Therapeutics (NASDAQ:ORKA) Trading Down 5.9%Here's Why - MarketBeat
Q2 EPS Estimate for Oruka Therapeutics Boosted by Analyst - MarketBeat
Oruka Therapeutics prices upsized $700M public offering at $72.50 per share - MSN
Oruka Therapeutics (ORKA) price target increased by 34.40% to 91.96 - MSN
Oruka Therapeutics (ORKA) sells 9.66M shares at $72.50 in underwritten deal - Stock Titan
Oruka Therapeutics (ORKA) Reports Positive Phase 2a Results for Psoriasis Treatment ORKA-001 - Yahoo Finance
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Up 22.4% in April - MarketBeat
Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque PsoriasisSlideshow (NASDAQ:ORKA) 2026-04-29 - Seeking Alpha
Oruka Therapeutics (ORKA) offers 9.66M shares, raising ~$658M net - Stock Titan
Oruka Therapeutics (NASDAQ:ORKA) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Moody Aldrich Partners LLC Takes $3.84 Million Position in Oruka Therapeutics, Inc. $ORKA - MarketBeat
H.C. Wainwright raises Oruka Therapeutics price target to $120 on trial data - Investing.com Canada
Oruka Therapeutics Shares Surpass Record High After Psoriasis Trial - HarianBasis.co
Oruka Therapeutics Prices Upsized $700 Million Share Offering - marketscreener.com
UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Raises Target Price to $100 - Moomoo
Oruka Therapeutics prices $700M stock offering at $72.50/share By Investing.com - Investing.com Australia
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering - The Manila Times
Oruka Therapeutics prices $700M stock offering at $72.50/share - Investing.com
Oruka Therapeutics, Inc. Prices Upsized Public Offering of 9.66 Million Shares at $72.50 Per Share - Quiver Quantitative
Oruka Therapeutics announces pricing of upsized $700 million underwritten public offering - marketscreener.com
Biotech Oruka locks in $700M cash raise at $72.50 a share - Stock Titan
Oruka Therapeutics Announces Pricing Of Upsized $700 Million Underwritten Public Offering - TradingView
Oruka Therapeutics (NASDAQ:ORKA) Trading 6.6% HigherWhat's Next? - MarketBeat
ORKA stock is soaring after psoriasis trial results — here's why BTIG hiked its price target by 94% - MSN
OGN Soars 16.87%, ORKA Hits Record on Healthcare Catalysts - Gotrade
UBS Lifts Price Target on Oruka Therapeutics to $100 From $75, Maintains Buy Rating - marketscreener.com
Oruka reports positive data from Phase IIa trial for plaque psoriasis - Yahoo
Oruka Therapeutics stock hits 52-week high at 90.06 USD By Investing.com - Investing.com South Africa
Oruka Therapeutics Touts “Category-Winning” ORKA-001 Data, Targets Once-Yearly Psoriasis Dosing - MarketBeat
5 Stocks Racking Up Monster Gains - Insider Monkey
Oruka Therapeutics (ORKA) Hits Record High on Stellar Clinical Trial Result - Yahoo Finance
Oruka’s ORKA-001 achieves 63.5% complete skin clearance in trial - Investing.com UK
Oruka Therapeutics stock explodes as psoriasis data shows 'highly compelling' skin clearance - MSN
New data suggest Oruka’s IL-23 mAb could be competitive in psoriasis - BioCentury
Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million - TechStock²
Oruka Therapeutics (ORKA) seeks to sell common stock under shelf prospectus - Stock Titan
Oruka Therapeutics (ORKA) registers $500M shelf for stock and warrants - Stock Titan
Clear Street raises Oruka Therapeutics price target on trial results By Investing.com - Investing.com Canada
Oruka Therapeutics launches $500 million stock offering By Investing.com - Investing.com Australia
Oruka Therapeutics launches $500M public offering with warrants option - MSN
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering - The Manila Times
Oruka Therapeutics launches $500 million stock offering - Investing.com
Biotech Oruka seeks $500M sale, with option for $75M more - Stock Titan
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):